ABSTRACT
D
espite widespread acceptance of endovascular coil embolization for aneurysms, rates of unfavorable angiographic outcomes remain relatively high. A recent systematic review of coiling literature reported a rate of 18% of such outcomes. 1 In an effort to improve long-term occlusion rates, a number of "modified," second-generation coil types have been developed and marketed. Numerous single-center case series have been published regarding outcomes for each of these second-generation coil types, including Matrix (Boston Scientific, Natick, Massachusetts), [2] [3] [4] HydroCoil (MicroVention, Tustin, California), [5] [6] [7] and Cerecyte coils (Codman Neurovascular, Raynham, Massachusetts). 8, 9 In addition, outcomes from several randomized, controlled trials (RCTs) of the major coil types have recently been reported. [10] [11] [12] To date, relatively few literature reviews of second-generation coils have been published, and such reviews rarely if ever have implemented formal meta-analytic procedures. 13, 14 In this current study, we report results from a systematic review and metaanalysis assessing differences in reported unfavorable angiographic outcomes for cerebral aneurysms treated with coil embolization as a function of coil type.
MATERIALS AND METHODS
The methodology and reporting of this systematic review follows the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) statement. 15 
Literature Search
We searched Ovid MEDLINE and EMBASE databases from January 1999 to December 2011. The search was performed by an experienced reference librarian. The following key words as Medical Subject Headings (MeSH) terms and text words were used in relevant combinations: "subarachnoid hemorrhage," "intracranial aneurysm," "endovascular treatment," and "coiling" in both "AND" and "OR" combinations. In addition, we reviewed abstracts from selected radiology, neurology, and neurosurgery scientific meetings in the years 2011 and 2012 to identify coil studies (the 2012 annual meeting of the American Society of Neuroradiology, the 2011 annual meeting of the Society of Neurointerventional Surgery, and the 2011 annual meeting of the Congress of Neurologic Surgeons).
Inclusion criteria were 1) Ͼ50 aneurysms reported, 2) coil type clearly specified and noted to be either bare platinum, Matrix, HydroCoils, or Cerecyte coils, and 3) available imaging follow-up with DSA or MR angiography. If both MRA and DSA outcomes were available, we included DSA results. If DSA was not available, MR angiography was then used.
Exclusion criteria were 1) traumatic, dissecting, mycotic, or flowrelated aneurysms, 2) treatment with other coil types or lack of clarity regarding coil type used, primarily stent-treated aneurysms, or noncoil embolic agents used to perform either aneurysm or parent vessel coil occlusions. When studies had multiple groups comparing different imaging modalities (eg, DSA, MRA), only the groups that were followed with DSA were considered. When the same patient population was the subject of multiple publications, only the study with the largest cohort was included in this analysis.
The primary outcome was "unfavorable" angiographic outcome, defined as any degree of recanalization noted on the follow-up images with comparison to the immediate posttreatment results. Terms such as "aneurysm recurrence," "new filling of aneurysm lumen," and "regrowth" were considered synonymous with "recanalization." If "recanalization" was not reported in a study, then the "unfavorable angiographic outcome" was defined as either Ͻ90% degree of occlusion or class 3 on the Raymond scale (incomplete occlusion), which is defined as any opacification of the sac. 16 We considered the longest duration of reported angiographic results for each study when more than 1 phase of follow-up was reported. Each of 2 reviewers (I.R., G.M.) independently evaluated the articles in the librarian's primary list and selected studies that fulfilled the inclusion criteria. In the case of a disagreement, D.F.K. reviewed and adjudicated inclusion. For each study, we extracted number of coiled aneurysms, number of aneurysms that had available follow-up, mean aneurysm size, initial rupture status, mean duration of follow-up, use of a core laboratory facility, whether assessed by single or multiple readers, angiographic follow-up outcomes, and coil types.
In this present review, we classified 4 types of coils: bare platinum, Matrix, HydroCoil, and Cerecyte. Guglielmi detachable coils were considered to be equivalent to bare platinum coils. Matrix coils included all Matrix subtypes (Matrix 1, Matrix 2, Matrix ACTIVE, and Matrix POST-ACTIVE). The HydroCoil group included studies that used either HydroCoil or HydroSoft. Cerecyte studies were considered as Cerecyte when their use was clearly stated in the methods.
Statistical Analysis
We used the analysis of variance test to compare baseline group characteristics (mean aneurysm size, proportion of initially ruptured aneurysms, and mean follow-up duration). We calculated the rates of unfavorable angiographic outcomes from each study. The confidence intervals of the rates were estimated by the Jeffreys method. 17 We used the DerSimonian and Laird random effects method to pool the overall rate of unfavorable outcome as well as the rate of unfavorable outcome for each coil type. 18, 19 To compare rates of unfavorable outcomes among coil types, we used the test of interaction proposed by Altman and Bland. 20 We also constructed multivariate nested random effects meta-regression models to further explore the difference of coil types after adjusting for baseline characteristics. 19 We used the I 2 statistic and the Cochran Q test to measure the overall heterogeneity, which refers to the variations of study outcomes across the studies. I 2 Ͼ50% and a conservative P value (P Ͻ .10) suggest high heterogeneity. 21 The Tau 2 statistic was adopted to measure the variance across studies. We also used the R 2 statistic to measure the proportion of total variance explained by each coil type. With the use of the Egger regression asymmetry test, we also assessed whether our findings were likely to be biased by the tendency that significant results are more likely to be published, so-called publication bias. 22 All statistical analyses were conducted with the use of STATA version 12 (StataCorp, College Station, Texas). We used the GRADE framework to evaluate the overall quality of the evidence (ie, confidence in the estimates).
23,24
Study Quality
The quality of the included studies was assessed by use of the New castle-Ottawa Quality Assessment Scale. 25 We selected the scale items relevant to uncontrolled studies, such as most the included studies, and therefore quality evaluation focused on the following items: representativeness of the exposed cohort to the population at hand (truly or somewhat representative versus selected groups or no description), selection of the nonexposed cohort (drawn from the same population versus not or no description), ascertainment of exposure (coiling procedure recorded), assessment of the outcome (independent versus self-report), length of follow-up (Ͼ6 months or Ͻ6 months), and loss to follow-up (Ͼ75% of the studied aneurysms were followed versus less). 
RESULTS
We identified 4019 potential references published between January 1999 and December 2011 as well as 3 prospective coil studies identified from 2011-2012 conference proceedings 11, 12, 26 (Fig 1) . There was a disagreement on 8 studies (0.2%) between the 2 reviewers that was resolved by a decision from the senior author. A total of 3940 studies (97%) of 4022 were excluded for the following reasons: Ͻ50 treated aneurysms (2887 articles; 72%), no available angiographic follow-up (746 articles; 19%), nonclinical series (editorial letters, nonhuman experimental models for cerebral aneurysms) (256 articles; 6%), utilization of coil types other than the designated included categories or treatment options other than coiling, such as stents alone or parent artery occlusion (30 articles; 0.8%), and duplicate publishing of the same patient population (21 articles; 0.5%). As such, 82 (2%) studies met all inclusion criteria and were included in our analysis (see On-line Appendix for full list of included studies). Seventy-four (90%) of the 82 studies described patients treated with a single coil type. The remaining 8 studies of the included 82 (10%) compared 2 subsets of patient groups that were treated with 2 different coil types. Each subset was considered a separate patient subgroup. In total, there were 90 patient subgroups.
The total number of treated aneurysms was 17,706, of which 12,986 (73%) had available angiographic follow-up outcomes and were included in the final analysis. The overall mean aneurysm size was 8.0 mm (interquartile range [IQR]: 4.6 -15 mm).
The average percentage of ruptured aneurysms in the enrolled studies was 64% (IQR: 11-100%). The patients were followed up to 18.9 months (IQR: 4.5-69 months) on average.
Sixty-five (72%) of 90 patient subgroups were treated with bare platinum coils, 8 subgroups (8.9%) were treated with Matrix coils, 11 (12%) were treated with HydroCoils, and 6 (6.7%) were treated with Cerecyte. Table 1 summarizes baseline characteristics of the studied groups. The differences among coil types were not significant regarding mean aneurysm size (P ϭ .69), the proportion of initially ruptured aneurysms (P ϭ .58), or the mean duration of follow-up (P ϭ .08).
The pooled rates of unfavorable outcomes are shown in Fig 2. Overall, the rate of unfavorable outcomes from all studies was 19% (95% CI: 17%, 21%) (2452 of 12,986 aneurysms). For bare platinum coils, the rate was 20% (95% CI: 17%, 22%) (1907 of 10,370 aneurysms), for Matrix it was 23% (95% CI: 16%, 29%) (279 of 1128 aneurysms), for HydroCoil it was 15% (95% CI: 8.7%, 21%) (175 of 977 aneurysms), and for Cerectye it was 15% (95% CI: 6.6%, 23%) (91 of 511 aneurysms). The difference in rates across various coil types was not statistically significant (P ϭ .32). Even after adjusting for baseline rupture, aneurysm size, follow-up time, core laboratory, and multiple-reader interpretation effect, we found no significant differences in the reported unfavorable outcomes rates between coil types (Table 2) .
Across studies, substantial heterogeneity was observed in all pooled outcome estimates (I 2 Ͼ50%, P Ͻ .001) (Fig 2) . The Egger regression asymmetry test suggested potential publication bias (P Ͻ .001). The quality of the included studies is summarized in Fig 3. Only 3 (3.7%) of 82 studies were RCTs. 10, 12 The remaining studies were observational cohort studies with or without a control group. Fig 3 summarizes the quality of the included studies. Selection of nonexposed cohorts was not adequate because most of the studies described a single-center series of patients with no control group. The assessment of outcome was self-reported except for 8 (9.8%) of 82 studies in which an independent core laboratory reported the angiographic outcomes. The other items were found to be adequate in the included studies. The overall quality of the current evidence (ie, confidence in the estimates) is low, considering the observational nature of most of the studies, heterogeneity, and the likelihood of publication bias.
DISCUSSION
In the current study, with the use of formal meta-analytic tools, we found that reported rates of unfavorable angiographic outcomes were not significantly different among the various leading types of endovascular coils for aneurysm therapy. Overall, approximately 1 in 5 aneurysms showed unfavorable outcome at follow-up. At first glance, both HydroCoil and Cerecyte rates appear to be superior to bare platinum and Matrix, with the former coil types showing 15% and the latter coil types showing 20% unfavorable outcome rates. However, given the relatively small numbers of aneurysms, even when pooling studies, the confidence intervals for all reported proportions were wide and thus significant differences were not shown. The results from this current study were further compromised by substantial heterogeneity among studies as well as by signals of potential publication bias. Taken together, these results suggest that clear differences among coil type have yet to be manifest and that implementation of future, high-quality, prospective studies remains of paramount importance.
Previous studies have failed to demonstrate consensus regarding the relative advantages of second-generation coils compared with bare platinum coils. Whereas some previous studies were encouraging for improved outcomes, 7,27-30 others were not as promising. 13, 31, 32 Three recent RCTs compared bare platinum coils with each of the leading modified coils, including HydroCoil, 10 Matrix, 11 and Cerecyte coils. 12 The HELPS trial found a slight improvement in major recurrences among aneurysms that were treated with HydroCoils. However, the MAPS and Cerecyte trials found no significant advantages of newer devices over bare platinum. Previous reviews of the literature have assessed possible advantages of Matrix coils 13 and other second-generation coils. 14 The results of our current study are relatively consistent with previous studies, in that none has found significant differences between coil types on angiographic follow-up. However, our current study improves on this prior literature in several ways. First, previous studies comprised studies up to the year 2005 13 or 2007 14 ; therefore, our results bring the evidence base up to date.
Furthermore, with the use of formal meta-analytic techniques, we accounted for potential confounding variables such as aneurysm size, baseline rupture status, and duration of follow-up, all of which can impact rates of unfavorable angiographic outcome. Finally, our data point to substantial heterogeneity as well as potential publication bias, which mandate that all of these results should undergo careful scrutiny by practitioners. Our study has many limitations. The heterogeneity of the studies in the literature forced us to combine patients that were followed by either DSA or MR angiography despite possible technique-related variations and combine multiple types of unfavorable results, including incomplete occlusion and Raymond class 3, with recanalization. Also, most studies were excluded for incomplete reporting of outcomes. We did not consider other variables that would potentially affect outcomes, including proportion of wide-necked aneurysms and anatomic location. The lack of statistical significance may also be due underpowered subgroup analyses and should not be interpreted as equivalence of the different coil types. Finally, in this systematic review, we found only 3 RCTs. Observational studies are subject to high risk of bias be- cause of baseline imbalance and potential outcome confounding. By pooling results from observational studies and RCTs, ecological bias may have affected our results. Further studies are clearly needed to provide higher quality evidence.
CONCLUSIONS
The rate of unfavorable angiographic outcomes of cerebral aneurysms treated with coil embolization was not statistically different across the major approved coil types. 
